COX-2 (human recombinant)

Stability : 6 months
Description :
The expression of COX-2 was assayed by RT-PCR and Western blot after HepG2 and BEL7402 cells were transfected with liposomes for 24, 48, 72 and 96 hours. Results The shRNA express vectors had been successfully constructed by restriction endonuclease analysis and DNA sequencing. The transfection rates in HepG2 and BEL7402 cells after 48 hours were about 60% and 54% respectively.The inhibition efficiencies of plasmid WBH1 in HepG2 and BEL7402 by RT-PCR were 18.5%, 88.6%, 52.8%, 42.4%(P<0.01) and 9%, 45.1%, 70.1%, 56.3% (P<0.01), compared with those of the control at 24, 48, 72 and 96 hours.The inhibition efficiencies of plasmid WBH1 in HepG2 and BEL7402 cells by Western blot were 10.2%, 80.5%, 45.3%, 39.0% (P<0.01) and 8.3%, 40.2%, 66.4%,35.6%at 24, 48, 72 and 96 hours(P<0.01). The plasmid WBH2 had no effect on COX-2 expression. Conclusion COX-2 expression in human hepatocellular carcinoma cells can be inhibited significantly by construction of eukaryotic expression vector expressing the shRNA. The inhibitory effect is highly related with selection of target sequence. Part II: ShRNA targeted to COX-2 influence the adhesion and invasion of human hepatocellular carcinoma cell line HepG2 Objective To study the effect of COX-2 shRNA on the cell adhension and invasion in human hepatocellular carcinoma cell line HepG2 in vitro. Methods The plasmids WBH1 and HK were transfected into HepG2 cells .The untransfected cells were used as control group.
Purity : >70%
Storage : -80°C